Actilyse 20

Package leaflet: Information for the user

Actilyse 10, 10 mg, powder and solvent for solution for infusion
Actilyse 20, 20 mg, powder and solvent for solution for infusion
Actilyse 50, 50 mg, powder and solvent for solution for infusion
Alteplase
Please read all of this leaflet carefully before this medicine is administered, because it contains
important information for the patient.

• Keep this leaflet, as you may need to read it again.
• If you have any further questions, please ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed for a specific individual. Do not pass it on to others. It may harm someone else, even if their symptoms are the same.
• If the patient experiences any adverse reactions, including any not listed in this leaflet, inform a doctor, pharmacist, or nurse immediately. See section 4.

Contents of the leaflet

1. What Actilyse is and what it is used for
2. What you need to know before using Actilyse
3. How to use Actilyse
4. Possible side effects
5. How to store Actilyse
6. Contents of the pack and other information

1. What Actilyse is and what it is used for

The active substance in Actilyse is alteplase. It belongs to a group of medicines called thrombolytic agents. These medicines work by dissolving blood clots that have formed in blood vessels.
Actilyse 10, 20, or 50 are used in the treatment of several conditions caused by blood clots in blood vessels, including:

• heart attack caused by blood clots in the arteries of the heart (acute myocardial infarction)
• blood clots in the arteries of the lungs (acute massive pulmonary embolism)
• stroke caused by blood clots in the brain's arteries (acute ischaemic stroke).

2. Important information before using Actilyse

When not to use Actilyse

• if the patient is allergic to the active substance alteplase or to any of the other ingredients of this medicine (listed in section 6).
• if the patient currently has or has recently had a disease that increases the risk of bleeding, including:
  • bleeding disorders or tendency to bleed
  • severe or life-threatening bleeding in any part of the body
  • intracranial haemorrhage or bleeding into the brain
  • uncontrolled, very high blood pressure
  • bacterial infections or inflammation of the heart (endocarditis), or inflammation of the membranes surrounding the heart (pericarditis)
  • acute pancreatitis
  • peptic ulcer of the stomach or intestines
• oesophageal varices
• blood vessel disorders, such as local enlargement of an artery (aneurysm)
• certain tumours
• severe liver disease
  • if the patient is taking blood-thinning medicines (oral anticoagulants), unless appropriate tests have confirmed no clinically significant anticoagulant activity
  • if the patient has ever undergone brain or spinal cord surgery
  • if the patient has undergone major surgery within the past 3 months
  • if the patient has recently undergone procedures involving puncture of large blood vessels
  • if the patient has undergone external cardiac massage within the past 10 days
  • if the patient has given birth within the past 10 days.

Additionally, Actilyse must not be used in the treatment of heart attack or blood clots in the
pulmonary arteries:

• if the patient has ever had a stroke caused by bleeding into the brain (haemorrhagic stroke)
• if the patient has ever had a stroke of unknown cause
• if the patient has recently (within the past 6 months) had a stroke caused by a blood clot in a brain artery (ischaemic stroke), unless this is the stroke currently being treated.

Additionally, Actilyse must not be used in the treatment of stroke caused by blood clots in the
cerebral artery (acute ischaemic stroke):

• if the onset of ischaemic stroke symptoms occurred more than 4.5 hours ago, or if it is possible that symptoms began more than 4.5 hours ago, because the exact time of onset is unknown
• if the stroke causes only mild symptoms
• if symptoms of bleeding into the brain are present
• if the patient has had a stroke within the past 3 months
• if symptoms have improved rapidly before administration of Actilyse
• if the patient has had a very severe stroke
• if the patient has had seizures (fits) at the time of stroke onset
• if the activated partial thromboplastin time (a blood test measuring blood clotting) is abnormal. This test may be abnormal if the patient has received heparin (a medicine used to "thin" the blood) within the past 48 hours
• if the patient has diabetes and has ever had a stroke
• if the platelet count (thrombocytes) in the blood is very low
• if the patient has very high blood pressure (above 185/110 mmHg), which can only be reduced by injection of medicines
• if the blood sugar (glucose) level is very low (below 50 mg/dl, equivalent to < 2.8 mmol/l)
• if the blood sugar (glucose) level is very high (above 400 mg/dl, equivalent to > 22.2 mmol/l)
• if the patient is under 16 years of age (patients aged ≥ 16 years, see section Warnings and precautions).

Warnings and precautions

• if the patient has had an allergic reaction other than a sudden, life-threatening allergic reaction (severe hypersensitivity reaction) to the active substance alteplase or to any of the other ingredients of this medicine (listed in section 6)
• if the patient currently has or has recently had any other conditions that increase the risk of bleeding, such as:
  • minor injuries
  • biopsy (a procedure to obtain a tissue sample)
  • puncture of large blood vessels
  • intramuscular injections
• external cardiac massage
  • if the patient has previously received Actilyse
  • if the patient is over 65 years of age
  • in elderly patients (over 80 years of age), treatment outcomes may be somewhat poorer regardless of treatment, and the risk of intracranial haemorrhage during thrombolytic therapy may be higher compared to younger patients. Overall, the benefit-risk ratio in elderly patients remains positive. Thrombolytic therapy in patients with acute ischaemic stroke should be evaluated based on individual benefit-risk assessment.
  • in children aged ≥ 16 years, individual benefit-risk assessment should be carefully performed. Children aged ≥ 16 years should be treated according to adult guidelines after confirmation of thromboembolic arterial ischaemic stroke (excluding stroke mimics).

Actilyse with other medicines
Tell the doctor about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take. In particular, inform the doctor if the patient is currently taking or has recently taken:

• any medicines used to "thin" the blood, including:
  • acetylsalicylic acid
  • warfarin
  • coumarins
  • heparin
• certain medicines used to treat high blood pressure (ACE inhibitors).

Pregnancy, breastfeeding and fertility
If the patient is pregnant or breastfeeding, suspects she may be pregnant, or is planning to have a child, she should consult her doctor or pharmacist before using this medicine. The doctor will use Actilyse only if the expected benefit of treatment outweighs the potential risk to the unborn child.

3. How to use Actilyse

Actilyse should always be prepared and used according to the doctor's instructions.
The medicine is not intended for self-administration.
Administration of Actilyse should begin as soon as possible after the onset of first symptoms.
There are three indications for which this medicine may be administered:

Heart attack (myocardial infarction)
The dose used depends on body weight. The maximum dose of Actilyse is 100 mg, but it is lower in patients with body weight below 65 kg.
The medicine may be administered using one of two dosing regimens:
a) 90-minute dosing regimen in patients who can begin treatment within 6 hours of symptom onset
Administration consists of:

• initial intravenous bolus injection of a portion of the Actilyse dose
• infusion of the remaining portion over the next 90 minutes

b) 3-hour dosing regimen in patients who can begin treatment between 6 and 12 hours after symptom onset
Administration consists of:

• initial intravenous bolus injection of a portion of the Actilyse dose
• infusion of the remaining portion over the next 3 hours

Additionally, the doctor will administer another medicine to reduce blood clot formation. This medicine will be given as soon as possible after the onset of chest pain.

Blood clots in the pulmonary arteries (pulmonary embolism)
The dose used depends on body weight. The maximum dose of Actilyse is 100 mg, but it is lower in patients with body weight below 65 kg.
The medicine is usually administered as:

• initial intravenous bolus injection of a portion of the dose
• infusion of the remaining portion over the next 2 hours

After treatment with Actilyse, the doctor will start (or restart) treatment with heparin (a medicine used to "thin" the blood).

Stroke caused by blood clots in the brain artery (acute ischaemic stroke)
Actilyse must be administered within 4.5 hours of the onset of first symptoms. The earlier Actilyse is administered, the greater the benefit from treatment and the lower the risk of adverse effects. The maximum dose of the medicine is 90 mg, but it is lower in patients with body weight below 100 kg.
Actilyse is administered as:

• initial intravenous bolus injection of a portion of the dose
• infusion of the remaining portion over the next 60 minutes

Acetylsalicylic acid should be avoided during the first 24 hours after administration of Actilyse in stroke treatment. If necessary, the doctor may decide to administer heparin.

Administration of a higher than recommended dose of Actilyse
If the maximum recommended dose is exceeded, the risk of intracranial bleeding increases.
In cases of severe bleeding, transfusion of fresh frozen plasma is recommended. Synthetic antifibrinolytic agents may also be administered.

If you have any further questions regarding the use of this medicine, consult your doctor.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone will experience them.
Below is a list of adverse reactions reported in people who have been treated with Actilyse:

Very common (occur in more than 1 in 10 patients receiving the medicine)

• heart failure – treatment may need to be discontinued
• bleeding into the brain after treatment of stroke caused by a blood clot in a cerebral artery (acute ischaemic stroke) – treatment may need to be discontinued
• presence of fluid in the lungs (pulmonary oedema)
• bleeding from a damaged blood vessel (such as haematoma)
• low blood pressure (hypotension)
• chest pain (angina)

Common (occur in less than 1 in 10 patients receiving the medicine)

• recurrent heart attack
• bleeding into the brain after treatment of heart attack (myocardial infarction) – treatment may need to be discontinued
• cardiac arrest (circulatory arrest) – treatment may need to be discontinued
• shock (very low blood pressure) due to heart failure – treatment may need to be discontinued
• bleeding into the throat
• bleeding into the stomach or intestines, including vomiting blood or blood in stool, rectal bleeding, bleeding from gums
• bleeding into tissues causing purple bruises (purpura)
• bleeding from urinary tract or reproductive organs, which may lead to presence of blood in urine (haematuria)
• bleeding or bruising (haematoma) at the injection site

Uncommon (occur in less than 1 in 100 patients receiving the medicine)

• blood-stained sputum (haemoptysis)
• nosebleed
• irregular heartbeat after restoration of blood flow to the heart
• damage to heart valves (mitral regurgitation) or to the wall separating the heart chambers (ventricular septal defect) – treatment may need to be discontinued
• sudden blockage of an artery in the lungs (pulmonary embolism), brain (cerebral embolism), or in any other part of the body (peripheral embolism)
• bleeding from the ear
• decreased blood pressure

Rare (occur in less than 1 in 1000 patients receiving the medicine)

• bleeding from the lungs
• bleeding into the pericardium – the sac surrounding the heart (pericardial haemorrhage) – treatment may need to be discontinued
• internal bleeding into the retroperitoneal space (retroperitoneal haemorrhage) – treatment may need to be discontinued
• formation of blood clots in blood vessels which may travel to other organs (embolism). Symptoms depend on the organs affected.
• allergic reactions, e.g. urticaria and rash, breathing difficulties associated with asthma (bronchospasm), fluid accumulation under the skin and mucous membranes (angioedema), low blood pressure or shock – treatment may need to be discontinued
• bleeding into the eye
• nausea

Very rare (occur in less than 1 in 10,000 patients receiving the medicine)

• severe allergic reaction (e.g. life-threatening anaphylactic reaction) – treatment may need to be discontinued
• neurological events such as:
  • seizures (fits, epileptic seizures)
  • speech disorders
  • confusion or delirium (very severe confusion)
  • anxiety with agitation
  • depression
  • cognitive disturbances (psychosis)
    These disorders often occur in connection with stroke caused by blood clots or bleeding in the brain.

Frequency not known (frequency cannot be estimated from available data)

• bleeding in internal organs, e.g. bleeding in the liver – treatment may need to be discontinued
• formation of cholesterol emboli which may travel to other organs (cholesterol embolism). Symptoms depend on the organs affected – treatment may need to be discontinued
• bleeding requiring blood transfusion
• vomiting
• increased body temperature (fever)

Death or permanent disability may occur as a result of bleeding into the brain or other serious bleeding.

Reporting of adverse reactions
If any adverse reactions occur, including any not listed in this leaflet, tell your doctor, pharmacist, or nurse. Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49-21-301, fax: +48 22 49-21-309, website: https://smz.ezdrowie.gov.pl. Adverse reactions can also be reported to the marketing authorisation holder. By reporting adverse reactions, you help provide more information on the safety of this medicine.

5. How to store Actilyse

Usually there is no need for the patient to store Actilyse, as it is administered by a physician.
The medicine should be stored out of the sight and reach of children.
Do not store above 25 °C. Store in the outer packaging to protect from light.
Do not use Actilyse after the expiry date stated on the container. The expiry date refers to the last day of the stated month.

Chemical and physical stability after preparation
The prepared solution has been shown to be stable for 24 hours at a temperature of 2 °C to 8 °C and for up to 8 hours at a temperature below 25 °C.

Microbiological stability after preparation
From a microbiological point of view, the medicinal product should be used immediately after preparation. If the product is not used immediately, the duration and conditions of storage prior to use are the responsibility of the user, but should not exceed 24 hours when stored in a refrigerator at a temperature of 2 °C to 8 °C.

6. Contents of the pack and other information

What Actilyse contains

• The active substance is alteplase. One vial contains 10 mg (5800000 IU Actilyse 10), 20 mg (11600000 IU Actilyse 20), or 50 mg (29000000 IU Actilyse 50) of alteplase.
• The other ingredients are: L-arginine, phosphoric acid (for pH adjustment), polysorbate 80.
• The solvent is water for injections.

What Actilyse looks like and contents of the pack
Actilyse is a powder and solvent for solution for infusion.
Each pack contains one vial of powder and one vial of solvent.
Vials made of Type I glass with bromobutyl rubber stoppers, in a cardboard box.
Pack type and size:
Actilyse 10 1 vial containing 10 mg alteplase
1 vial of solvent – water for injections 10 ml
Actilyse 20 1 vial containing 20 mg alteplase
1 vial of solvent – water for injections 20 ml
Actilyse 50 1 vial containing 50 mg alteplase
1 vial of solvent – water for injections 50 ml
Not all pack sizes may be marketed.

Marketing Authorisation Holder:
Boehringer Ingelheim International GmbH
Binger Strasse 173
D-55216 Ingelheim/Rhein
Germany

Manufacturer:
Boehringer Ingelheim Pharma GmbH & Co. KG
Birkendorfer Strasse 65
88397 Biberach/Riss
Germany
Boehringer Ingelheim France
100-104 avenue de France
75013 Paris
France

For further information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:

Poland
Boehringer Ingelheim Sp. z o.o.
Tel. + 48 22 699 0 699

Information intended exclusively for medical professionals:

Identifiability
To improve the traceability of medicinal biological products, the name and batch number of the administered product should be clearly documented.

Reconstitution
To obtain a final concentration of 1 mg alteplase per 1 mL, transfer the entire volume of the provided solvent into the vial containing the powder. For medicinal products with strengths of 20 mg and 50 mg, a solvent transfer cannula is included. For the 10 mg medicinal product, a syringe should be used.

To obtain a final concentration of 2 mg alteplase per 1 mL, transfer only half the volume of the solvent (as shown in the table below). For this purpose, use a sy游戏副本

The prepared solution should be administered intravenously. The prepared 1 mg/ml solution may be further diluted with sterile sodium chloride 9 mg/ml (0.9%) injection solution to a minimum concentration of 0.2 mg/ml, since the formation of turbidity cannot be excluded. Further dilution of the prepared 1 mg/ml solution with sterile water for injections or with carbohydrate infusion solutions, e.g. glucose, is not recommended due to increased risk of turbidity. Actilyse must not be mixed with other medicinal products in the same infusion vial (this also includes heparin).
Storage conditions – see section 5 of the package leaflet.
The prepared solution is for single use only. Any unused medicinal product or waste material must be disposed of in accordance with local regulations.
Reconstitution instructions for Actilyse

1	Reconstitution must be performed immediately before administration.
2	Remove by prying with the thumb the protective caps from two vials containing Water for Injections and Actilyse powder.
3	Wipe the rubber stopper of each vial with an alcohol swab.
4	Remove the cannula* from its packaging. Do not disinfect or sterilize the cannula; it is sterile. Remove one cap.
5	Place the vial of Water for Injections upright on a stable surface. Using the cannula, puncture vertically from the top at the center of the rubber stopper with gentle but firm pressure, without twisting.
6	Hold with one hand the vial of Water for Injections and the cannula using the double-sided wings. Remove the remaining cap from the top of the cannula.
7	Hold with one hand the vial of Water for Injections and the cannula using the double-sided wings. Holding the powder vial upright above the cannula, place the tip of the cannula in the center of the stopper. Press the powder vial down firmly from above onto the cannula, piercing the rubber stopper vertically, gently but firmly, without twisting.
8	Invert both vials and allow the water to flow completely into the powder vial.
9	Remove the empty vial together with the cannula. These components may be discarded.
10	Take the reconstituted Actilyse vial and gently swirl to dissolve any remaining powder. Do not shake, as this may cause foaming. If bubbles appear, leave the solution undisturbed for a few minutes until they disappear.
11	The reconstituted solution contains 1 mg/ml Actilyse. It should be clear, colorless to pale yellow, and free from particles.
12	Withdraw the appropriate amount using only a needle and syringe. To avoid leakage, do not use the puncture site left by the cannula.
13	Use immediately. Discard any unused portion of the solution.

(* if the cannula is connected to the set. Reconstitution may also be performed using a needle and syringe.)
Dosage and administration
Acute myocardial infarction
Dosage
a) 90-minute (accelerated) dosage regimen in patients with acute myocardial infarction, in whom treatment can be initiated within 6 hours from symptom onset
In patients with body weight ≥ 65 kg:

For patients with body weight < 65 kg, the dose should be appropriately adjusted according to the following scheme:

b) 3-hour dosing regimen for patients with acute myocardial infarction, in whom treatment can be initiated within 6 to 12 hours from the onset of symptoms:
In patients with body weight ≥ 65 kg:

For patients with body weight < 65 kg:

Adjunctive therapy:
Adjunctive anticoagulant therapy is recommended according to current guidelines for
patients with ST-segment elevation myocardial infarction.
Method of administration
The reconstituted solution should be administered intravenously. The solution is intended for immediate use.
Acute massive pulmonary embolism
Dosing
In patients with body weight ≥ 65 kg:
A total dose of 100 mg should be administered over 2 hours. The greatest experience has been obtained using the following dosing regimen:

In patients with body weight < 65 kg:

Supportive treatment:
After thrombolytic therapy with Actilyse, heparin treatment should be initiated (or resumed) if
the APTT value does not exceed twice the upper limit of normal.
Treatment should be monitored by measuring APTT (an APTT prolonged 1.5 to 2.5 times the
baseline value indicates an appropriate heparin dose).

Method of administration
The reconstituted solution must be administered intravenously. The solution is intended for immediate use.

Acute ischaemic stroke
Treatment must be carried out only under the supervision of physicians trained and experienced in neurology (see sections 4.3 and 4.4 of the Summary of Product Characteristics).
Treatment must be initiated as early as possible within 4.5 hours of symptom onset (see section 4.4 of the Summary of Product Characteristics). After 4.5 hours from symptom onset, the benefit-risk ratio associated with the use of Actilyse is unfavourable; therefore, the medicinal product should not be administered (see section 5.1 of the Summary of Product Characteristics).

Dosing
The recommended total dose is 0.9 mg alteplase/kg body weight (maximum 90 mg), with 10% of the total dose given as an initial intravenous bolus injection, followed immediately by the remainder of the total dose as an intravenous infusion over 60 minutes.

Dosing table for the treatment of acute ischaemic stroke

| Body weight (kg) | Total dose (mg) | Bolus dose (mg) | Infusion dose (mg)* | |------------------|-----------------|-----------------|---------------------| | 40 | 36.0 | 3.6 | 32.4 | | 42 | 37.8 | 3.8 | 34.0 | | 44 | 39.6 | 4.0 | 35.6 | | 46 | 41.4 | 4.1 | 37.3 | | 48 | 43.2 | 4.3 | 38.9 | | 50 | 45.0 | 4.5 | 40.5 | | 52 | 46.8 | 4.7 | 42.1 | | 54 | 48.6 | 4.9 | 43.7 | | 56 | 50.4 | 5.0 | 45.4 | | 58 | 52.2 | 5.2 | 47.0 | | 60 | 54.0 | 5.4 | 48.6 | | 62 | 55.8 | 5.6 | 50.2 | | 64 | 57.6 | 5.8 | 51.8 | | 66 | 59.4 | 5.9 | 53.5 | | 68 | 61.2 | 6.1 | 55.1 | | 70 | 63.0 | 6.3 | 56.7 | | 72 | 64.8 | 6.5 | 58.3 | | 74 | 66.6 | 6.7 | 59.9 | | 76 | 68.4 | 6.8 | 61.6 | | 78 | 70.2 | 7.0 | 63.2 | | 80 | 72.0 | 7.2 | 64.8 | | 82 | 73.8 | 7.4 | 66.4 | | 84 | 75.6 | 7.6 | 68.0 | | 86 | 77.4 | 7.7 | 69.7 | | 88 | 79.2 | 7.9 | 71.3 | | 90 | 81.0 | 8.1 | 72.9 | | 92 | 82.8 | 8.3 | 74.5 | | 94 | 84.6 | 8.5 | 76.1 | | 96 | 86.4 | 8.6 | 77.8 | | 98 | 88.2 | 8.8 | 79.4 | | 100+ | 90.0 | 9.0 | 81.0 |

*administered at a concentration of 1 mg/ml over 60 minutes

Supportive treatment
There have been insufficient studies on the safety and efficacy of the above dosing regimen in combination with concomitant administration of heparin or platelet aggregation inhibitors such as acetylsalicylic acid within the first 24 hours after onset of ischaemic stroke symptoms.
Intravenous heparin or platelet aggregation inhibitors such as acetylsalicylic acid should be avoided within the first 24 hours after administration of Actilyse due to the increased risk of bleeding.
If heparin treatment is required for other indications (e.g. prevention of deep vein thrombosis), the dose of subcutaneously administered heparin should not exceed 10,000 IU per day.

Method of administration
The reconstituted solution must be administered intravenously. The solution is intended for immediate use.